Bone marrow biopsy does not add value to PET/CT staging of DLBCL
The use of PET/CT imaging accurately assessed bone marrow involvement in most patients with diffuse large B-cell lymphoma, according to retrospective study results. {read more here}
In the detection and characterization of lung lesions 10 mm or larger, 18F-FDG PET/MRI and 18F-FDG PET/CT perform comparably. Lesion size, SUV and characterization correlate strongly between the two modalities. However, the overall detection rate of PET/MRI remains inferior to that of PET/CT because of the limited ability of MRI to detect lesions smaller than 10 mm. Thus, thoracic staging with PET/MRI bears a risk of missing small lung metastases. {read more here}
A radiotracer recently cleared for PET imaging of recurrent prostate cancer may have similar efficacy for certain forms of breast cancer, according to a study presented at last week’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting. {read more here}
FDG-PET/CT’s ability to find a significant number of distant metastases in patients with newly diagnosed clinical stage IIB triple-negative breast cancer suggests that current guidelines from the National Comprehensive Cancer Network (NCCN) for the modality’s use may need to be revised. {read more here}